Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Central Review Likely For Novel Surrogate Endpoints

This article was originally published in The Pink Sheet Daily

Executive Summary

CDER’s Woodcock says accelerated approval requirements in 21st Century Cures legislation could create a process akin to how FDA handles breakthrough designations.


Related Content

PDUFA Budgeting: What Will Get Added, Subtracted – Or Multiplied By Cures?
Cures Excitement May Wane While Senate Works
Surrogate Endpoints Only Have ‘Limited’ Evidence On Cancer Survival, Review Concludes
Exclusivity Incentives In Cures Bill Not Overwhelmingly Costly, CBO Says
‘Breakthrough’ Fee Eyed As Deterrent To Frivolous Requests
Senator Tells FDA To Create ‘Red Team’ For Regulatory Streamlining
FDA Flexible With Accelerated Approval Evidence, Analysis Finds
Biomarkers For Rare Diseases Get Scaled-Back Plea In New White Paper
Biomarkers In Orphan Studies Still Need Past Experience, FDA Says
CDER Medical Policy Council Balances “Breakthrough” Requests With Broader Issues





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts